| 1. |
- Poley, L., et al.
(författare)
-
The ABC130 barrel module prototyping programme for the ATLAS strip tracker
- 2020
-
Ingår i: Journal of Instrumentation. - : IOP PUBLISHING LTD. - 1748-0221 .- 1748-0221. ; 15:9
-
Tidskriftsartikel (refereegranskat)abstract
- For the Phase-II Upgrade of the ATLAS Detector [1], its Inner Detector, consisting of silicon pixel, silicon strip and transition radiation sub-detectors, will be replaced with an all new 100% silicon tracker, composed of a pixel tracker at inner radii and a strip tracker at outer radii. The future ATLAS strip tracker will include 11,000 silicon sensor modules in the central region (barrel) and 7,000 modules in the forward region (end-caps), which are foreseen to be constructed over a period of 3.5 years. The construction of each module consists of a series of assembly and quality control steps, which were engineered to be identical for all production sites. In order to develop the tooling and procedures for assembly and testing of these modules, two series of major prototyping programs were conducted: an early program using readout chips designed using a 250 nm fabrication process (ABCN-250) [2, 3] and a subsequent program using a follow-up chip set made using 130 nm processing (ABC130 and HCC130 chips). This second generation of readout chips was used for an extensive prototyping program that produced around 100 barrel-type modules and contributed significantly to the development of the final module layout. This paper gives an overview of the components used in ABC130 barrel modules, their assembly procedure and findings resulting from their tests.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Vanzella, E., et al.
(författare)
-
An extremely metal-poor star complex in the reionization era : Approaching Population III stars with JWST
- 2023
-
Ingår i: Astronomy and Astrophysics. - 0004-6361 .- 1432-0746. ; 678
-
Tidskriftsartikel (refereegranskat)abstract
- We present JWST/Near Infrared Spectrograph (NIRSpec) integral field spectroscopy (IFS) of a lensed Population III candidate stellar complex (dubbed Lensed And Pristine 1, LAP1), with a lensing-corrected stellar mass of ≲104 M⊙ and an absolute luminosity of MUV > −11.2 (mUV > 35.6), confirmed at redshift 6.639 ± 0.004. The system is strongly amplified (μ ≳ 100) by straddling a critical line of the Hubble Frontier Field galaxy cluster MACS J0416. Although the stellar continuum is currently not detected in the Hubble and JWST/Near Infrared Camera (NIRCam) and Near Infrared Imager and Slitless Spectrograph (NIRISS) imaging, arclet-like shapes of Lyman and Balmer lines, Lyα, Hγ, Hβ and Hα are detected with NIRSpec IFS with signal-to-noise ratios (S/N) of approximately 5 − 13 and large equivalent widths (> 300 − 2000 Å), along with a remarkably weak [O III]λλ4959, 5007 at S/N ≃ 4. LAP1 shows a large ionizing photon production efficiency, log(ξion[erg Hz−1]) > 26. From the metallicity indexes R23 = ([O III] + [O II])/Hβ ≲ 0.74 and R3 = ([O III]/Hβ) = 0.55 ± 0.14, we derive an oxygen abundance of 12 + log(O/H)≲6.3. Intriguingly, the Hα emission is also measured in mirrored subcomponents where no [O III] is detected, providing even more stringent upper limits on the metallicity if in situ star formation is ongoing in this region (12 + log(O/H) < 6). The formal stellar mass limit of the subcomponents would correspond to ∼103 M⊙ or MUV fainter than −10. Alternatively, this metal-free, pure line-emitting region could be the first case of a fluorescing H I gas region induced by transverse escaping ionizing radiation from a nearby star complex. The presence of large equivalent-width hydrogen lines and the deficiency of metal lines in such a small region make LAP1 the most metal-poor star-forming region currently known in the reionization era and a promising site that may host isolated, pristine stars.
|
|
| 5. |
- Akiba, K., et al.
(författare)
-
Measurement of thermal properties of the LHCb VELO detector using track-based software alignment
- 2023
-
Ingår i: Journal of Instrumentation. - : Institute of Physics (IOP). - 1748-0221 .- 1748-0221. ; 18:10
-
Tidskriftsartikel (refereegranskat)abstract
- The thermal properties of the LHCb Vertex Locator (VELO) are studied using the real-time detector alignment procedure. The variation of the position and orientation of the detector elements as a function of the operating temperature of the VELO is presented. This study uses a dataset collected by the LHCb experiment during a VELO temperature scan performed at the end of LHC Run 2 (October 2018). Significant shrinkage of the VELO modules is observed at the operating temperature of -30(degrees)C compared to the laboratory measurements on a single module taken at a range of temperatures from +45(degrees)C to -25(degrees)C. The thermal shrinkage expected from the extrapolation of laboratory measurements to lower temperatures, and the results of this alignment study are in good agreement.
|
|
| 6. |
|
|
| 7. |
- Sánchez Van Kammen, Mayte, et al.
(författare)
-
Characteristics and Outcomes of Patients with Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia
- 2021
-
Ingår i: JAMA Neurology. - : American Medical Association. - 2168-6149 .- 2168-6157. ; 78:11, s. 1314-1323
-
Tidskriftsartikel (refereegranskat)abstract
- Importance: Thrombosis with thrombocytopenia syndrome (TTS) has been reported after vaccination with the SARS-CoV-2 vaccines ChAdOx1 nCov-19 (Oxford-AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson).Objective: To describe the clinical characteristics and outcome of patients with cerebral venous sinus thrombosis (CVST) after SARS-CoV-2 vaccination with and without TTS.Design, Setting, and Participants: This cohort study used data from an international registry of consecutive patients with CVST within 28 days of SARS-CoV-2 vaccination included between March 29 and June 18, 2021, from 81 hospitals in 19 countries. For reference, data from patients with CVST between 2015 and 2018 were derived from an existing international registry. Clinical characteristics and mortality rate were described for adults with (1) CVST in the setting of SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia, (2) CVST after SARS-CoV-2 vaccination not fulling criteria for TTS, and (3) CVST unrelated to SARS-CoV-2 vaccination.Exposures: Patients were classified as having TTS if they had new-onset thrombocytopenia without recent exposure to heparin, in accordance with the Brighton Collaboration interim criteria.Main Outcomes and Measures: Clinical characteristics and mortality rate.Results: Of 116 patients with postvaccination CVST, 78 (67.2%) had TTS, of whom 76 had been vaccinated with ChAdOx1 nCov-19; 38 (32.8%) had no indication of TTS. The control group included 207 patients with CVST before the COVID-19 pandemic. A total of 63 of 78 (81%), 30 of 38 (79%), and 145 of 207 (70.0%) patients, respectively, were female, and the mean (SD) age was 45 (14), 55 (20), and 42 (16) years, respectively. Concomitant thromboembolism occurred in 25 of 70 patients (36%) in the TTS group, 2 of 35 (6%) in the no TTS group, and 10 of 206 (4.9%) in the control group, and in-hospital mortality rates were 47% (36 of 76; 95% CI, 37-58), 5% (2 of 37; 95% CI, 1-18), and 3.9% (8 of 207; 95% CI, 2.0-7.4), respectively. The mortality rate was 61% (14 of 23) among patients in the TTS group diagnosed before the condition garnered attention in the scientific community and 42% (22 of 53) among patients diagnosed later.Conclusions and Relevance: In this cohort study of patients with CVST, a distinct clinical profile and high mortality rate was observed in patients meeting criteria for TTS after SARS-CoV-2 vaccination..
|
|
| 8. |
- Scutelnic, Adrian, et al.
(författare)
-
Management of Cerebral Venous Thrombosis Due to Adenoviral COVID-19 Vaccination.
- 2022
-
Ingår i: Annals of neurology. - : Wiley. - 1531-8249 .- 0364-5134. ; 92:4, s. 562-573
-
Tidskriftsartikel (refereegranskat)abstract
- Cerebral venous thrombosis (CVT) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus-based severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non-heparin anticoagulants, and avoidance of platelet transfusion. The aim of this study was to evaluate adherence to these recommendations and its association with mortality.We used data from an international prospective registry of patients with CVT after the adenovirus-based SARS-CoV-2 vaccination. We analyzed possible, probable, or definite VITT-CVT cases included until January 18, 2022. Immunomodulation entailed administration of intravenous immunoglobulins and/or plasmapheresis.Ninety-nine patients with VITT-CVT from 71 hospitals in 17 countries were analyzed. Five of 38 (13%), 11 of 24 (46%), and 28 of 37 (76%) of the patients diagnosed in March, April, and from May onward, respectively, were treated in-line with VITT recommendations (p<0.001). Overall, treatment according to recommendations had no statistically significant influence on mortality (14/44 [32%] vs 29/55 [52%], adjusted odds ratio [OR]=0.43, 95% confidence interval [CI]=0.16-1.19). However, patients who received immunomodulation had lower mortality (19/65 [29%] vs 24/34 [70%], adjusted OR=0.19, 95% CI=0.06-0.58). Treatment with non-heparin anticoagulants instead of heparins was not associated with lower mortality (17/51 [33%] vs 13/35 [37%], adjusted OR=0.70, 95% CI=0.24-2.04). Mortality was also not significantly influenced by platelet transfusion (17/27 [63%] vs 26/72 [36%], adjusted OR=2.19, 95% CI=0.74-6.54).In patients with VITT-CVT, adherence to VITT treatment recommendations improved over time. Immunomodulation seems crucial for reducing mortality of VITT-CVT. ANN NEUROL 2022;92:562-573.
|
|
| 9. |
- Vanzella, E., et al.
(författare)
-
Probing the circumstellar medium 2.8 Gyr after the big bang : detection of Bowen fluorescence in the Sunburst arc
- 2020
-
Ingår i: Monthly Notices of the Royal Astronomical Society: Letters. - London : Oxford University Press. - 1745-3925 .- 1745-3933. ; 499:1, s. L67-L71
-
Tidskriftsartikel (refereegranskat)abstract
- We discovered Bowen emission arising from a strongly lensed (i.e., with magnification factor μ>20) source hosted in the Sunburst arc at z=2.37. We claim this source is plausibly a transient stellar object and study the unique ultraviolet lines emerging from it. In particular, narrow (σ_v ~ 40 km/s) ionisation lines of Fe fluoresce after being exposed to Lya radiation that pumps selectively their atomic levels. Data from VLT/MUSE, X-Shooter and ESPRESSO observations (the latter placed at the focus of the four UTs) at increasing spectral resolution of R=2500, 11400 and R=70000, respectively, confirm such fluorescent lines are present since at least 3.3 years (~ 1 year rest-frame). Additional Fe forbidden lines have been detected, while C and Si doublets probe an electron density n_e >~ 106 cm−3. Similarities with the spectral features observed in the circum-stellar Weigelt blobs of Eta-Carinae probing the circum-stellar dense gas condensations in radiation-rich conditions are observed. We discuss the physical origin of the transient event, which remains unclear. We expect such transient events (including also supernova or impostors) will be easily recognised with ELTs thanks to high angular resolution provided by adaptive optics and large collecting area, especially in modest (μ<3) magnification regime.
|
|
| 10. |
- Zahoranszky-Kohalmi, G., et al.
(författare)
-
Workflow of Integrated Resources to Catalyze Network Driven COVID-19 Research
- 2022
-
Ingår i: Journal of Chemical Information and Modeling. - : American Chemical Society (ACS). - 1549-9596 .- 1549-960X. ; 62:3, s. 718-729
-
Tidskriftsartikel (refereegranskat)abstract
- In the event of an outbreak due to an emerging pathogen, time is of the essence to contain or to mitigate the spread of the disease. Drug repositioning is one of the strategies that has the potential to deliver therapeutics relatively quickly. The SARS-CoV-2 pandemic has shown that integrating critical data resources to drive drug-repositioning studies, involving host-host, host-pathogen, and drug-target interactions, remains a time-consuming effort that translates to a delay in the development and delivery of a life-saving therapy. Here, we describe a workflow we designed for a semiautomated integration of rapidly emerging data sets that can be generally adopted in a broad network pharmacology research setting. The workflow was used to construct a COVID-19 focused multimodal network that integrates 487 host-pathogen, 63 278 host- host protein, and 1221 drug-target interactions. The resultant Neo4j graph database named "Neo4COVID19" is made publicly accessible via a web interface and via API calls based on the Bolt protocol. Details for accessing the database are provided on a landing page (https://neo4covid19.ncats.io/). We believe that our Neo4COVID19 database will be a valuable asset to the research community and will catalyze the discovery of therapeutics to fight COVID-19.
|
|
